Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Ischaemic endpoints

Published byElvin Jackson Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1 Ischaemic endpoints"— Presentation transcript:

1 Figure 1 Ischaemic endpoints
Figure 1 Ischaemic endpoints. The overall population, the stable (stable coronary artery disease), and the unstable (acute coronary syndrome) subgroups are shown, with hazard ratios and 95% confidence intervals, for the primary endpoint of death for any cause, myocardial infarction (MI), or cerebrovascular accident (CVA), cardiovascular (CV) death or myocardial infarction, death for any cause and myocardial infarction (Death/MI), definite stent thrombosis (def ST) and definite/probable stent thrombosis (Def/prob ST) among patients randomly assigned to either the 6-month or the 24-month dual-antiplatelet therapy. From: Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial Eur Heart J. 2015;36(20): doi: /eurheartj/ehv038 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please

2 Figure 2 Cumulative incidence of ischaemic and bleeding events
Figure 2 Cumulative incidence of ischaemic and bleeding events. Cumulative incidence curves are shown. (A) Death for any cause, myocardial infarction, or cerebrovascular accident in the stable and unstable group of the two treatment arms. (B) Bleeding according to the Bleeding Academic Research Consortium 2, 3, 5 criteria, in the stable and unstable group of the two treatment arms. From: Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial Eur Heart J. 2015;36(20): doi: /eurheartj/ehv038 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please

3 Figure 3 Bleeding endpoints
Figure 3 Bleeding endpoints. The overall population, the stable (stable coronary artery disease), and the unstable (acute coronary syndrome) subgroups are shown, with hazard ratios and 95% confidence intervals, for the key safety endpoint of Bleeding Academic Research Consortium 2, 3, 5 bleeding, and further safety outcomes of Bleeding Academic Research Consortium 3 or 5, TIMI major and minor (TIMI MA/MIN), and GUSTO moderate and severe (GUSTO MOD/SEV) bleeding among patients randomly assigned to either the 6-month or the 24-month clopidogrel therapy. From: Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial Eur Heart J. 2015;36(20): doi: /eurheartj/ehv038 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please

4 Figure 4 Net adverse clinical event
Figure 4 Net adverse clinical event. The overall population, the stable (stable coronary artery disease), and the unstable (acute coronary syndrome) subgroups are shown, with hazard ratios and 95% confidence intervals, for the net adverse clinical events of death for any cause, myocardial infarction, cardiovascular accident, or Bleeding Academic Research Consortium class 2, 3, 5 bleeding (NACE BARC 2–5), and for death for any cause, myocardial infarction, cardiovascular accident, or Bleeding Academic Research Consortium class 3, 5 bleeding (NACE BARC 3–5) among patients randomly assigned to either the 6-month or the 24-month clopidogrel therapy. From: Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial Eur Heart J. 2015;36(20): doi: /eurheartj/ehv038 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please

5 Figure 5 Cumulative incidence of net adverse clinical event
Figure 5 Cumulative incidence of net adverse clinical event. Cumulative incidence curves are shown for the net adverse clinical events consisting of death for any cause, myocardial infarction, cerebrovascular accident, and Bleeding Academic Research Consortium class 2, 3, 5 bleeding. (A) Acute coronary syndrome subgroup and (B) stable coronary artery disease subgroup. From: Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial Eur Heart J. 2015;36(20): doi: /eurheartj/ehv038 Eur Heart J | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author For permissions please

Download ppt "Figure 1 Ischaemic endpoints"

Similar presentations

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.

Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.

Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.
PRODIGY Objective Study Design Primary Composite Endpoint

PRODIGY Objective Study Design Primary Composite Endpoint
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.

Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.

RESOLUTE US One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Objective To evaluate the clinical effectiveness of the Resolute.
¨ 8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin.

¨ 8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.

Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
M. Valgimigli, MD, PhD University of Ferrara, ITALY On behalf of the PRODIGY Investigators PROlonging Dual antiplatelet treatment after Grading stent-induced.

M. Valgimigli, MD, PhD University of Ferrara, ITALY On behalf of the PRODIGY Investigators PROlonging Dual antiplatelet treatment after Grading stent-induced.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.

European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction †

Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction †
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.

Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.
수요저널 2015. 5. 13 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.
Randomized, non-inferiority trial of three limus agent- eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results:

Randomized, non-inferiority trial of three limus agent- eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results:
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38.

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38.

Similar presentations

Ads by Google